JP2014506790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506790A5 JP2014506790A5 JP2013552669A JP2013552669A JP2014506790A5 JP 2014506790 A5 JP2014506790 A5 JP 2014506790A5 JP 2013552669 A JP2013552669 A JP 2013552669A JP 2013552669 A JP2013552669 A JP 2013552669A JP 2014506790 A5 JP2014506790 A5 JP 2014506790A5
- Authority
- JP
- Japan
- Prior art keywords
- mutant
- heteromultimeric protein
- igg antibody
- modified igg
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000018102 proteins Nutrition 0.000 claims 26
- 102000004169 proteins and genes Human genes 0.000 claims 26
- 108090000623 proteins and genes Proteins 0.000 claims 26
- 102000004851 Immunoglobulin G Human genes 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 17
- 230000004048 modification Effects 0.000 claims 10
- 238000006011 modification reaction Methods 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 10
- 125000000539 amino acid group Chemical group 0.000 claims 8
- 238000005734 heterodimerization reaction Methods 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 229960005190 Phenylalanine Drugs 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000006143 cell culture media Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 125000003607 serino group Chemical group [H]OC(=O)C([H])(N([H])*)C([H])([H])O[H] 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Claims (26)
- 野生型FcポリペプチドのFc変異体を含む変異体ヘテロ多量体タンパク質又は修飾型IgG抗体であって、前記Fc変異体が、前記野生型FcポリペプチドのFc領域に少なくとも二のアミノ酸修飾を含み、前記変異体タンパク質が、野生型Fcポリペプチドと比較した場合に、誤対合の減少、頭尾形成の減少、又は全収率の増大を示す、前記変異体ヘテロ多量体タンパク質又は前記修飾型IgG抗体。
- ノブ・イントゥー・ホール修飾を更に含む、請求項1に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- 野生型FcポリペプチドのFc変異体を含む変異体ヘテロ多量体タンパク質又は修飾型IgG抗体であって、前記Fc変異体が、少なくとも一の重鎖の残基241及び243(EU番号付け)で、野生型Fcポリペプチドに存在するものと異なるアミノ酸との置換を含み、それにより、残基241及び243(EU番号付け)で置換が無いヘテロ多量体又はIgG抗体と比較した場合に、誤対合の減少、頭尾形成の減少、又は全収率の増大を生じる、前記変異体ヘテロ多量体タンパク質又は前記修飾型IgG抗体。
- 少なくとも一の重鎖において、F241R/F243S及びF241S/F243Rから選択される変異を含む、請求項3に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- ノブ・イントゥー・ホール修飾を更に含む、請求項3又は請求項4に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- ノブ修飾が、Fcポリペプチドの界面からの元のアミノ酸残基を、元のアミノ酸残基よりも大きい側鎖を持つアミノ酸残基と置換することを含み、アミノ酸残基の置換が、トリプトファン、フェニルアラニン、チロシン及びアルギニンからなる群から選択される、請求項5に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- ノブ修飾がT366W置換(EU番号付け)を含む、請求項5又は請求項6に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- ホール修飾が、Fcポリペプチドの界面からの元のアミノ酸残基を、元のアミノ酸残基よりも小さい側鎖を持つアミノ酸残基と置換することを含み、置換するアミノ酸残基が、セリン、スレオニン、バリン及びアラニンからなる群から選択される、請求項5から7の何れか一項に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- ホール修飾が、T366S、L368A及びY407V(EU番号付け)からなる群から選択される二又はそれ以上のアミノ酸置換を含む、請求項8に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- F241R/F243S又はF241S/F243R置換を含む重鎖が、ノブ修飾を更に含む、請求項5から9の何れか一項に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- F241R/F243S又はF241S/F243R置換を含む重鎖が、ホール修飾を更に含む、請求項5から10の何れか一項に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- 両方の重鎖がF241R/F243S又はF241S/F243R置換を含む、請求項5から11の何れか一項に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- タンパク質又は抗体が多重特異性抗体である、請求項1から12の何れか一項に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体。
- 請求項1から13の何れか一項に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体をコードする単離された核酸。
- 請求項14に記載の核酸を含む発現ベクター。
- 請求項14に記載の核酸分子を含む宿主細胞、又は請求項15に記載の発現ベクター。
- 請求項1から16の何れか一項に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体を産生する宿主細胞。
- CHO細胞、又は大腸菌細胞である、請求項16又は17に記載の宿主細胞。
- 変異体ヘテロ多量体タンパク質又は修飾型IgG抗体を産生する方法であって、請求項16又は17に記載の宿主細胞を培養し、該細胞培養液から変異体ヘテロ多量体タンパク質又は修飾型IgG抗体を回収することを含む方法。
- 請求項1から19の何れか一項に記載の変異体ヘテロ多量体タンパク質又は修飾型IgG抗体を含む組成物。
- 第一のヘテロ二量体化ドメインを有する第一のFc含有ポリペプチド、及び第二のヘテロ二量体化ドメインを有する第二のFc含有ポリペプチドを含むヘテロ多量体タンパク質を調製する方法であって、該第一及び/又は第二のFc含有ポリペプチドが残基241及び243(EU番号付け)で置換を含み、該方法が
(a)第一のヘテロ二量体化ドメインを有する精製された第一のFc含有ポリペプチドを提供し;
(b)第二のヘテロ二量体化ドメインを有する精製された第二のFc含有ポリペプチドを提供し;
(c)第一及び第二のFc含有ポリペプチドを結合し、及び
(d)第一のFc含有ポリペプチドを第二のFc含有ポリペプチドと再フォールディングし、ヘテロ多量体タンパク質を形成する工程を含む方法。 - ヘテロ多量体タンパク質を精製する工程を更に含む、請求項21に記載の方法。
- 第一及び/又は第二のFc含有ポリペプチドがF241R/F243S又はF241S/F243R置換を含む、請求項21又は請求項22に記載の方法。
- 第一及び/又は第二のFc含有ポリペプチドがノブ・イントゥー・ホール修飾を更に含む、請求項23に記載の方法。
- 請求項19に記載の方法により産生される、単離された変異体ヘテロ多量体タンパク質。
- 請求項21に記載の方法により産生される、単離されたヘテロ多量体タンパク質。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161439750P | 2011-02-04 | 2011-02-04 | |
US61/439,750 | 2011-02-04 | ||
PCT/US2012/023749 WO2012106587A1 (en) | 2011-02-04 | 2012-02-03 | Fc VARIANTS AND METHODS FOR THEIR PRODUCTION |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016132391A Division JP2017006128A (ja) | 2011-02-04 | 2016-07-04 | Fc変異体及びそれらの生産方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014506790A JP2014506790A (ja) | 2014-03-20 |
JP2014506790A5 true JP2014506790A5 (ja) | 2015-04-02 |
JP6161540B2 JP6161540B2 (ja) | 2017-07-12 |
Family
ID=45607400
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013552669A Active JP6161540B2 (ja) | 2011-02-04 | 2012-02-03 | Fc変異体及びそれらの生産方法 |
JP2016132391A Pending JP2017006128A (ja) | 2011-02-04 | 2016-07-04 | Fc変異体及びそれらの生産方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016132391A Pending JP2017006128A (ja) | 2011-02-04 | 2016-07-04 | Fc変異体及びそれらの生産方法 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2670776B1 (ja) |
JP (2) | JP6161540B2 (ja) |
KR (1) | KR101913448B1 (ja) |
CN (1) | CN103649117B (ja) |
AR (2) | AR085138A1 (ja) |
BR (1) | BR112013019499B1 (ja) |
CA (1) | CA2825064C (ja) |
HK (1) | HK1196020A1 (ja) |
MX (1) | MX355255B (ja) |
RU (2) | RU2018108836A (ja) |
WO (1) | WO2012106587A1 (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
PE20141114A1 (es) | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
EP2771364B1 (en) * | 2011-10-27 | 2019-05-22 | Genmab A/S | Production of heterodimeric proteins |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
CA2867824A1 (en) | 2012-05-01 | 2013-11-07 | Genentech, Inc. | Anti-pmel17 antibodies and immunoconjugates |
LT2968520T (lt) * | 2013-03-14 | 2021-09-27 | Macrogenics, Inc. | Bispecifinės molekulės, kurios yra imunoreaktyvios imuninių efektorių ląstelėms, kurios ekspresuoja aktyvuojantį receptorių |
KR102190220B1 (ko) * | 2013-05-29 | 2020-12-14 | 삼성전자주식회사 | 타겟 특이적 세포막 단백질 제거용 조성물 |
US9388243B2 (en) * | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
KR20160055252A (ko) | 2013-09-17 | 2016-05-17 | 제넨테크, 인크. | 항-lgr5 항체의 사용 방법 |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
WO2015117229A1 (en) * | 2014-02-07 | 2015-08-13 | Mcmaster University | Trifunctional t cell-antigen coupler and methods and uses thereof |
ES2955736T3 (es) | 2014-05-06 | 2023-12-05 | Hoffmann La Roche | Producción de proteínas heteromultiméricas usando células de mamífero |
KR102259232B1 (ko) * | 2014-08-25 | 2021-05-31 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
AR101844A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos y conjugados modificados genéticamente con cisteína |
TWI758784B (zh) | 2014-09-12 | 2022-03-21 | 美商建南德克公司 | 抗her2抗體及免疫結合物 |
WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
CN107124870A (zh) | 2014-09-17 | 2017-09-01 | 基因泰克公司 | 包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物 |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
JP2018534930A (ja) | 2015-10-30 | 2018-11-29 | ジェネンテック, インコーポレイテッド | 抗d因子抗体及びコンジュゲート |
CN108602884B (zh) | 2015-11-08 | 2024-06-25 | 豪夫迈·罗氏有限公司 | 筛选多特异性抗体的方法 |
PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
JP7022080B2 (ja) | 2016-05-27 | 2022-02-17 | ジェネンテック, インコーポレイテッド | 部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法 |
WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
CA3078637A1 (en) | 2017-10-12 | 2019-04-18 | Mcmaster University | T cell-antigen coupler with y182t mutation and methods and uses thereof |
KR102209108B1 (ko) | 2018-03-27 | 2021-01-28 | 국립암센터 | Oct4 기능 저해용 펩티드를 포함하는 줄기세포성 억제용 조성물 |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
EP3870235A1 (en) | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Conjugated chemical inducers of degradation and methods of use |
CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
AU2020275884A1 (en) * | 2019-05-16 | 2022-01-06 | Trustees Of Boston University | Regulated synthetic gene expression systems |
KR20220130678A (ko) | 2019-12-23 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 프로그라눌린 변이체들 |
MX2023000888A (es) | 2020-07-21 | 2023-02-22 | Genentech Inc | Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos. |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
EP4288458A1 (en) | 2021-02-03 | 2023-12-13 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
AU2022283819A1 (en) | 2021-06-01 | 2024-01-04 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 t cell-antigen couplers and uses thereof |
KR20240036076A (ko) * | 2021-08-13 | 2024-03-19 | 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 | Fcrn을 특이적으로 인식하는 항체 및 이의 용도 |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
SE8505922D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
ES2062519T5 (es) | 1989-03-21 | 2003-07-16 | Immune Response Corp Inc | Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
KR100216097B1 (ko) | 1989-07-19 | 1999-08-16 | 크리스토퍼 제이. 마골린 | 자가면역 및 악성종양질환 치료제로서의 t세포 수용체 펩티드 |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
IL96714A0 (en) | 1989-12-20 | 1991-09-16 | Schering Corp | Antibody antagonists of human interleukin-4 |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
HU221001B1 (hu) | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
DE69830901T2 (de) * | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
AU773891C (en) | 1998-10-23 | 2005-02-17 | Kirin-Amgen Inc. | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
US8372954B2 (en) | 2000-12-22 | 2013-02-12 | National Research Council Of Canada | Phage display libraries of human VH fragments |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
MXPA03010210A (es) | 2001-05-11 | 2004-03-10 | Amgen Inc | Peptidos y moleculas relacionadas que se enlazan a tall-1. |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
DK2345671T3 (en) * | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
US8084582B2 (en) * | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
CA2526085A1 (en) | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Treatment with anti-vegf antibodies |
JP5087274B2 (ja) | 2003-06-30 | 2012-12-05 | ドマンティス リミテッド | ポリペプチド |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
US7472724B2 (en) | 2003-08-18 | 2009-01-06 | Electrolock, Inc. | Method and apparatus for creating, using, and dispensing tubes |
SI1725249T1 (sl) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Spojine monometilvalina, sposobne konjugacije na ligande |
PL1718677T3 (pl) | 2003-12-19 | 2012-09-28 | Genentech Inc | Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze |
EP1703893B1 (en) | 2003-12-23 | 2012-04-11 | Genentech, Inc. | Novel anti-il 13 antibodies and uses thereof |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
CN101987870B (zh) * | 2004-07-15 | 2013-07-03 | 赞科股份有限公司 | 优化的Fc变体 |
PE20060560A1 (es) | 2004-08-03 | 2006-06-27 | Novartis Ag | Anticuerpos de interleucina-4 humana |
JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
JP2009515878A (ja) | 2005-11-12 | 2009-04-16 | イーライ リリー アンド カンパニー | 抗egfr抗体 |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
EP2087111A2 (en) * | 2007-03-19 | 2009-08-12 | Medimmune Limited | Polypeptide variants |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
JP5616428B2 (ja) * | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
-
2012
- 2012-02-03 BR BR112013019499-5A patent/BR112013019499B1/pt active IP Right Grant
- 2012-02-03 CN CN201280016878.3A patent/CN103649117B/zh active Active
- 2012-02-03 CA CA2825064A patent/CA2825064C/en active Active
- 2012-02-03 RU RU2018108836A patent/RU2018108836A/ru unknown
- 2012-02-03 WO PCT/US2012/023749 patent/WO2012106587A1/en active Application Filing
- 2012-02-03 EP EP12704198.6A patent/EP2670776B1/en active Active
- 2012-02-03 MX MX2013008920A patent/MX355255B/es active IP Right Grant
- 2012-02-03 AR ARP120100365A patent/AR085138A1/es active IP Right Grant
- 2012-02-03 KR KR1020137023274A patent/KR101913448B1/ko active IP Right Grant
- 2012-02-03 JP JP2013552669A patent/JP6161540B2/ja active Active
- 2012-02-03 RU RU2013140685/10A patent/RU2013140685A/ru not_active Application Discontinuation
-
2014
- 2014-09-19 HK HK14109443.8A patent/HK1196020A1/zh unknown
-
2016
- 2016-07-04 JP JP2016132391A patent/JP2017006128A/ja active Pending
-
2022
- 2022-10-31 AR ARP220102969A patent/AR127516A2/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014506790A5 (ja) | ||
RU2013140685A (ru) | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
JP7138046B2 (ja) | 二特異性抗体基幹 | |
JP2016026215A5 (ja) | ||
JP2020500015A5 (ja) | ||
JP2015146822A5 (ja) | ||
JP2005120106A5 (ja) | ||
JP2018085988A5 (ja) | ||
JP2012095652A5 (ja) | ||
JP2013531477A5 (ja) | ||
JP2007530435A5 (ja) | ||
JP2015212284A5 (ja) | ||
IL278014B1 (en) | Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use | |
JP2010273685A5 (ja) | ||
JP2020500510A5 (ja) | ||
JP2017529067A5 (ja) | ||
JP2014518883A5 (ja) | ||
JP2013537416A5 (ja) | ||
JP2011508604A5 (ja) | ||
JP2007513634A5 (ja) | ||
JP2010227116A5 (ja) | ||
JP2020505927A5 (ja) | ||
JP2016530236A5 (ja) | ||
JP2018512124A5 (ja) | ||
JP2020517260A5 (ja) |